임상 한눈에 보기

• 4건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 4건 · 완료/종료 0건
• Phase: Phase 1
• Status: Active, not recruiting · Recruiting
• 주요 endpoint: Toxicity profile of T-cell infusion as defined by all toxicities associated with T cells at the probably or definite levels · Dose-limiting toxicity (DLT) rate at the phase II recommended dose (RP2D) (CD19R(EQ)28zeta/EGFRt+ central memory T cells) · DLT rate at RP2D assessed using CTCAE version 4.0 for Arm II (CD19R(EQ)28zeta/EGFRt+ naive and memory T cells [TN/NEM]) · Complete response (CR) or CR with incomplete bone marrow recovery (CRi) with the exception of participants in CR or CRi that go from minimal residual disease (MRD) negative to MRD positive or progress as determined by the principal investigator · Detection of transferred T cells in the circulation for at least 28 days by quantitative-polymerase chain reaction (PCR)
• 등록 대상자(표본 합산): 약 172명

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.